2. Introduction
0 Pneumonia is an inflammation of the lung parenchyma
(i.e. alveoli rather than the bronchi) of infective origin.
12/12/2011 Pneumonia 2

3. 0 It is the most common infectious cause of death.
0 It is usually characterized by consolidation.
0 Consolidation is a pathological process in which the
alveoli are filled with a mixture of inflammatory exudate,
bacteria & WBC
12/12/2011 Pneumonia 3

4. EPIDEMIOLOGY
0Occurs throughout the year
0Results from different etiological agents
varying with the seasons
0Occurs in persons of all ages
0Clinical manifestations severe in very
young, elderly & in chronically ill patients
12/12/2011 Pneumonia 4

5. CLASSIFICATION
Classified based on two types
1. Type 1
0 Lobar pneumonia
0 Bronchopneumonia
2. Type 2
0 Community- acquired pneumonia (CAP)
0 Hospital-acquired pneumonia (HAP)
12/12/2011 Pneumonia 5

6. Lobar pneumonia
0 Lobar pneumonia is acute bacterial infection of a part of
lobe the entire lobe, or even two lobes of one or both
the lungs.
12/12/2011 Pneumonia 6

7. Bronchopneumonia
0 Bronchopneumonia is infection of the terminal
bronchioles that extends into the surrounding alveoli
resulting in patchy consolidation of the lung.
12/12/2011 Pneumonia 7

8. Community Acquired
Pneumonia (CAP)
Pneumonia which develops in an otherwise healthy
person outside of hospital or have been in hospital for
less than 48hrs
12/12/2011 Pneumonia 8

9. Nosocomial pneumonia
(HAP)
Pneumonia that was not incubating upon admission
developing in a patient hospitalized for greater than
48 hrs.
12/12/2011 Pneumonia 9

10. PATHOPHYSIOLOGY
Microbial invasion of the normally sterile lower respiratory
tract
Three routes-
0 Inhaled as aerosolized particles
0 Haematogenous spread from an extrapulmonary site of
infection
0 Aspiration of oropharyngeal contents
12/12/2011 Pneumonia 10

11. Various defence mechanisms
that protects lung from
infection
0 Anatomic barriers –epiglottis, larynx
0 Cough reflexes
0 Tracheobronchial secretions
0 Mucocilliary lining
0 Cell & humoral mediated immunity
0 Dual phagocytic system-alveolar macrophages &
neutrophils
12/12/2011 Pneumonia 11

12. Invasion occurs as a result of
0 Defect in host defence mechanism
0 Overwhelming inocculum
0 Lung infection with viruses suppress the
antibacterial activity of the lung by impairing
alveolar macrophage function & mucocilliary
clearance thus setting the stage for secondary
bacterial pneumonia.
12/12/2011 Pneumonia 12

13. Clinical Manifestations
0 Indolent to fulminant in presentation
0 Mild to fatal in severity
0 Typical symptoms –
• Fever
• Chills
• Cough
• Rust coloured sputum
• Mucopurulent sputum
• Dyspnea ( shortness of breath)
• Pleuritic chest pain
0 Elevated WBC
0 Bacteraemic
12/12/2011 Pneumonia 13

14. Chest X-ray
For Lobar Pneumonia
Consolidation
confined to
one or more
lobes (or
segments of
lobes) of
lungs.
Lobarpneumonia
12/12/2011 Pneumonia 14

15. Chest X-ray
For Bronchopneumonia
•Patchy
consolidation
usually in the
bases of both
lungs.
Bronchopneumonia
12/12/2011 Pneumonia 15

16. Diagnosis
Clinical diagnosis
0 History
0 Signs & symptoms
0 Chest x-ray
0 CT
12/12/2011 Pneumonia 16

17. Diagnosis
Etiological diagnosis
0 Gram's Stain and Culture of Sputum
0 Blood Cultures
0 Antigen Tests
0 Polymerase Chain Reaction
0 Serology
0 Bronchoalveolar lavage
0 Bronchoscopy
12/12/2011 Pneumonia 17

18. Complications
Possible complications include:
0 Acute respiratory distress syndrome (ARDS)
0 Fluid around the lung (pleural effusion)
0 Lung abscesses
0 Respiratory failure (which requires a breathing
machine or ventilator)
0 Sepsis, which may lead to organ failure
12/12/2011 Pneumonia 18

19. COMMUNITY ACQUIRED
PNEUMONIA
Pneumonia is most common in winter because of seasonal
increase in viral infections
Mortality
1%- Non hospitalized patients
13.7%-Hospiatalized patients
19.6%-Bacteremic patients
<36.5%- Intensive care unit
12/12/2011 Pneumonia 19

20. Risk factors
1. Comorbidity- Neoplastic disease, neurological
problem
2. Alcoholism
3. Advanced age
4. Asthma
5. Immunosuppression
12/12/2011 Pneumonia 20

21. Etiology
Potential etiologic agents in CAP - Bacteria
Viruses
Fungi
Protozoa
Potential bacteriologic causes can be divided into two
types
0 Typical bacterial pathogens
0 Atypical bacterial pathogens
12/12/2011 Pneumonia 21

22. Typical bacterial pathogens
0 Streptococcus pneumoniae – 30% to 60% ,Severe
illness, death
0 Haemophilus influenzae - 10%
0 S. aureus (in selected patients)
0 gram-negative bacilli –
Klebsiella pneumoniae
Pseudomonas aeruginosa
12/12/2011 Pneumonia 22

23. Atypical bacterial pathogens
0 Mycoplasma pneumoniae
0 Chlamydophila pneumoniae
0 Legionella pneumophillia
0 These organisms are intrinsically resistant to all - B
lactam agents macrolide, a fluoroquinolone, or a
tetracycline.
0 Poor dental hygiene-anaerobes
0 HIV- p.carnii
0 Birds- Chlamydia psittaci
0 Cattle or parturient cat-Coxiella burnetti
12/12/2011 Pneumonia 23

24. HOSPITAL ACQUIRED
PNEUMONIA
0 Pneumonia that was not incubating upon admission
developing in a patient hospitalized for greater than 48
hrs
0 10-15% of all hospital acquired pneumonia, usually
presenting with sepsis or&/or respiratory failure
0 50% acquired on ICU
12/12/2011 Pneumonia 24

25. Predisposing features
Reduced host defence against bacteria
0 Reduced immune defences (Corticosteroid treatment,
diabetes, malignancy)
0 Reduced cough reflux (Post operative)
0 Disordered mucocilliary clearance (Anaesthetic agents)
Aspiration of nasopharyngeal or gastric secretions
0 Immobility or reduced conscious level
0 Vomiting, Dysphagia,
0 Nasogastric intubation
12/12/2011 Pneumonia 25

26. 0 Most bacterial nosocomial infection occur by
microaspiration of bacteria colonizing the patients
oropharynx or upper GI tract
0 Most common pathogen – Aerobic gram negative bacilli
0 Most commonly exposed to multiresistant hospital
pathogen
0 86% nosocomial infection-mechanical ventilation
0 Mortality-0 to 50%
12/12/2011 Pneumonia 26

27. Bacterial introduction into LRT
Endotracheal intubation
Infected ventillatiors / nebuliser /bronchoscopy
Dental or sinus infection
Bacteraemia
Abdominal sepsis
Intravenous canula
12/12/2011 Pneumonia 27

28. Causative organisms
Common organisms
Gram negative bacteria-
0 Escherichia coli
0 Klebsiella sp.
0 Pseudomonas aeruginosa
Gram positive bacteria-
0 Streptococcus pneumoniae
0 Staphylococcus aureus
12/12/2011 Pneumonia 28

29. Less common organisms
1. Gram negative bacilli
other coliforms:Enterobacter sp.
0 Proteus sp.
0 Seratia marcescens
0 Citrobacter sp.
0 Acinobacter sp.
0 Legionella pneumophillia
2. Anaerobic bacteria
3. Fungi- Candida albicans Aspergillus fumigatus
4. Viruses- Cytomegalovirus (CMV), Herpes simplex
12/12/2011 Pneumonia 29

30. Treatment
Goals of therapy-
0 Eradication of the offending organism.
0 Selection of an appropriate antibiotic.
0 To minimize associated morbidity.
12/12/2011 Pneumonia 30

31. General approach to treatment
0 Adequacy of respiratory function
0 Humidified oxygen for hypoxemia
0 Bronchodilators (albuterol)
0 Chest physiotherapy with postural drainage
0 Adequate hydration if necessary
0 Expectorants such as guaifenesin
0 Chest pain- analgesics
12/12/2011 Pneumonia 31

32. Selection of an antimicrobial
agent
0 Empirical use of relatively broad spectrum antibiotic
0 Narrow spectrum antibiotics to cover specific
pathogen
0 Potential pathogens involved
0 Age
0 Previous &current medication history
0 Underlying disease
0 Present clinical status
12/12/2011 Pneumonia 32

33. Antibiotic doses for treating pneumonia
12/12/2011 Pneumonia 33

34. Treatment for special cases
1. Patient less than 60 years & without comorbidities:-
Azithromycine ( 500mg OD) *1day
( 250mg OD) *4days
Norfloxacin/Levofloxacin (400mg OD) *7days
2. Outpatient greater than 65 years:-
Norfloxacin (400mg OD) *7days or
Ceftriaxon (1-2 g/day) / Cifixim (2-4 g/day) 3rd gen
cefalosporins +
12/12/2011 Pneumonia 34

35. Macrolides like Azithromycin ( 500mg OD) *1day
( 250mg OD) *4days
3. Patient is hospitalised but not severely ill:-
Combination of 3rd gen cefalosporins + Macrolides
Ceftriaxone + Azithromycin
OR
Norfloxacin/Levofloxacin (400mg OD)
4. If the patient is hospitalised but not severely ill:-
Combination of 3rd gen cefalosporins + Macrolides
Ceftriaxone + Azithromycin
and newer fluroquinolones (Gatifloxacin)
12/12/2011 Pneumonia 35

36. 5. Patient hospitalised & severely ill:-
Combination of 3rd gen cefalosporins + Macrolides
Ceftriaxone + Azithromycin
and newer fluroquinolones (Gatifloxacin)
We can add Vancomycin.
6. Patient with icu admission:-
3rd gen cefalosporins + Fluroquinolones
(Gatifloxacin)
+
Nutritional supplements + Saline
Vancomycin/Meropenam
12/12/2011 Pneumonia 36

37. 7. For HAP:-
Cephalosporins + Aminoglycocides
8. For antipseudomons cephalosporins:-
Ceftazidime + Cefexime
12/12/2011 Pneumonia 37

38. Drugs with usual doses
12/12/2011 Pneumonia 38

39. 12/12/2011 Pneumonia 39

40. 12/12/2011 Pneumonia 40

41. 12/12/2011 Pneumonia 41